Viatris (VTRS) Income from Continuing Operations (2019 - 2026)
Viatris' (VTRS) quarterly Income from Continuing Operations came in at 176400000.0 in Q1 2026, up 105.8% year-on-year from 85714778.61 in Q1 2025, and up 151.87% quarter-over-quarter from 340100000.0 in Q4 2025.
Viatris (VTRS) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Viatris' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 176400000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 105.8% year-over-year to 176400000.0 in Q1 2026; TTM through Mar 2026 was 296500000.0, a 92.18% increase from a year earlier, with the FY2025 full-year figure at 3514900000.0, down 454.23% from the prior year.
- Income from Continuing Operations grew to 176400000.0 in Q1 2026 per VTRS's latest filing, from 340100000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1011200000.0 in Q4 2022 and bottomed at 3042000000.0 in Q1 2025.
- The 5-year median for Income from Continuing Operations is 113900000.0 (2024), against an average of 108200000.0.
- Across the five-year window, Income from Continuing Operations soared 483.32% in 2022 and slumped 2770.76% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 1011200000.0 in 2022, then slumped by 175.71% to 765600000.0 in 2023, then jumped by 32.54% to 516500000.0 in 2024, then jumped by 34.15% to 340100000.0 in 2025, then jumped by 151.87% to 176400000.0 in 2026.
- Per Business Quant, the three latest VTRS Income from Continuing Operations figures stand at 176400000.0 (Q1 2026), 340100000.0 (Q4 2025), and 128200000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | -22.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 176.40 Mn |
| Dec 31, 2025 | -340.10 Mn |
| Sep 30, 2025 | -128.20 Mn |
| Jun 30, 2025 | -4.60 Mn |
| Mar 31, 2025 | -3.04 Bn |
| Dec 31, 2024 | -516.50 Mn |
| Sep 30, 2024 | 94.80 Mn |
| Jun 30, 2024 | -326.40 Mn |
| Mar 31, 2024 | 113.90 Mn |
| Dec 31, 2023 | -765.60 Mn |
| Sep 30, 2023 | 331.60 Mn |
| Jun 30, 2023 | 264.00 Mn |
| Mar 31, 2023 | 224.70 Mn |
| Dec 31, 2022 | 1.01 Bn |
| Sep 30, 2022 | 354.30 Mn |
| Jun 30, 2022 | 313.90 Mn |
| Mar 31, 2022 | 399.20 Mn |
| Dec 31, 2021 | -263.80 Mn |
| Sep 30, 2021 | 311.50 Mn |
| Jun 30, 2021 | -279.20 Mn |